Saturday, July 11, 2026

Drug profile · INN

nafarelin acetate

nafarelin acetate (SYNAREL) is a gonadotropin-releasing hormone receptor agonist. Route of administration: nasal. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — nafarelin acetate
US status
approved
Class
Route
NASAL
Patents
0
Programs
0
Data quality
0.84

Quick answer

nafarelin acetate (SYNAREL) is a gonadotropin-releasing hormone receptor agonist. Route of administration: nasal. Current US regulatory status: approved.

Key facts

INN nafarelin acetate
Brand SYNAREL
Mechanism Gonadotropin-releasing hormone receptor agonist
Target Gonadotropin-releasing hormone receptor
Route NASAL
Formulation SPRAY, METERED

Mechanism of action

Gonadotropin-releasing hormone receptor agonist

Primary target: Gonadotropin-releasing hormone receptor

Approval history

Authority Status Date
FDA approved

Related & competitor drugs

  1. cetrorelix acetate Gonadotropin-releasing hormone receptor antagonist
  2. elagolix Gonadotropin-releasing hormone receptor antagonist
  3. ganirelix acetate Gonadotropin-releasing hormone receptor antagonist
  4. leuprolide acetate Gonadotropin-releasing hormone receptor agonist
  5. abarelix Gonadotropin-releasing hormone receptor antagonist
  6. degarelix acetate Gonadotropin-releasing hormone receptor antagonist

Frequently asked questions

What is nafarelin acetate?

nafarelin acetate (SYNAREL) is a gonadotropin-releasing hormone receptor agonist. Route of administration: nasal. Current US regulatory status: approved.

What is the brand name for nafarelin acetate?

SYNAREL is a marketed brand name for nafarelin acetate. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of nafarelin acetate?

nafarelin acetate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.